- English (USA)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
ProMIS Neurosciences Inc (PMN)
Track today's live ProMIS Neurosciences (PMN) share price, performance and key data on this page with our current NASDAQ:PMN stock exchange information. Analyse interactive charts and historical data, check technical buy and sell signals in real time, and follow the ProMIS Neurosciences share price on the NASDAQ exchange. Use the dropdown to switch exchange for the PMN share price, head to our technical summary section, which provides analysis on ProMIS Neurosciences share price buy/sell indicators using real-time data (or discuss the ProMIS Neurosciences (PMN) stock price today with other investors in the ProMIS Neurosciences NASDAQ share price and sentiment chat forum).
Use the dropdown to select a relevant stock exchange for the current NASDAQ:PMN share price (ISIN: CA74346M5054) to enhance your trading decisions with our free investment tools and resources.
What Is the ProMIS Neurosciences Inc Share Price Today?
The ProMIS Neurosciences share price today is 13.640.
What Is the Stock Symbol for ProMIS Neurosciences Inc
The stock symbol (or 'ticker') for ProMIS Neurosciences Inc is "PMN."
What Stock Exchange Does ProMIS Neurosciences Inc Trade On?
ProMIS Neurosciences Inc is listed and trades on the NASDAQ stock exchange.
Is ProMIS Neurosciences Inc a Good Stock to Buy?
Determining whether ProMIS Neurosciences (or any stock) is a good buy requires comprehensive market analysis. To evaluate its potential, investors can sign up to InvestingPro, where they can assess share price, fair value and more than 1,200 other metrics.
Use the dropdown to select a relevant stock exchange for the current NASDAQ:PMN share price (ISIN: CA74346M5054) to enhance your trading decisions with our free investment tools and resources.
What Is the ProMIS Neurosciences Inc Share Price Today?
The ProMIS Neurosciences share price today is 13.640.
What Is the Stock Symbol for ProMIS Neurosciences Inc
The stock symbol (or 'ticker') for ProMIS Neurosciences Inc is "PMN."
What Stock Exchange Does ProMIS Neurosciences Inc Trade On?
ProMIS Neurosciences Inc is listed and trades on the NASDAQ stock exchange.
Is ProMIS Neurosciences Inc a Good Stock to Buy?
Determining whether ProMIS Neurosciences (or any stock) is a good buy requires comprehensive market analysis. To evaluate its potential, investors can sign up to InvestingPro, where they can assess share price, fair value and more than 1,200 other metrics.
13.640
-0.725(-5.05%)
Real-time Data·
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
13.240
13.675
52 wk Range
6.270
27.400
PMN is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
13.24013.675
52 wk Range
6.27027.400
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
PMN Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceAnalysts Sentiment
Strong Buy
Price Target
43.903
Upside
+221.87%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Significant return over the last week
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Buy
Analyst Ratings
8 Buy
0 Hold
0 Sell
Ratings:
8 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 43.903
(+221.87% Upside)
ProMIS Neurosciences Inc Earnings Call Summary for Q2/2026
- ProMIS ended Q2 with CAD 53.4M cash vs CAD 6.1M at year-end 2025, sufficient to fund operations through 2027 and Q1 2027 data readout.
- Q2 net loss widened to CAD 11.7M (CAD 1.28/share) from CAD 10.1M (CAD 7.26/share) year-over-year, driven by increased clinical activity.
- Alzheimer's drug PMN310 showed positive interim safety data with zero ARIA-E cases; PRECISE-AD trial enrolled 144 patients across 21 U.S. sites.
- Management preparing for potential single registration study if Q1 2027 data remain positive; holds FDA Fast Track designation for PMN310.
- Pipeline expansion includes PMN267 for ALS and PMN442 for synucleinopathies, both expected to enter clinic within 6-9 months.
Last Updated: 13/08/2026, 22:50
Read Full TranscriptEarnings
Latest Release
13/08/2026
EPS / Forecast
-1.28 / -0.18
Revenue / Forecast
-- / --
Compare PMN to Peers and Sector
Metrics to compare | PMN | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipPMNPeersSector | |
|---|---|---|---|---|
P/E Ratio | −3.1x | −2.8x | −0.4x | |
PEG Ratio | 0.09 | −0.24 | 0.00 | |
Price/Book | 2.6x | 2.8x | 2.6x | |
Price / LTM Sales | - | 1.9x | 3.0x | |
Upside (Analyst Target) | 144.8% | 246.1% | 51.3% | |
Fair Value Upside | Unlock | 1.2% | 7.8% | Unlock |
ProMIS Neurosciences, Inc. discovers and develops antibody therapies and therapeutic vaccines for neurodegenerative diseases and other misfolded protein diseases in Canada. The company’s proprietary discovery platform comprises ProMIS, which enables drug discovery through a combination of protein biology, physics, and supercomputing. Its lead product candidates include PMN310, a monoclonal antibody (mAb) for toxic oligomers for treating Alzheimer's disease; PMN267 for the treatment of amyotrophic lateral sclerosis; and PMN442, a mAb targeting toxic a-syn oligomers and seeding fibrils for treating multiple system atrophy. The company also develops PNM440, an alpha-synuclein vaccine for treating multiple synucleinopathies; and PMN311, an amyloid-beta vaccine for the treatment of Alzheimer's. In addition, it is developing therapies for frontotemporal lobar degeneration, Huntington’s disease, progressive supranuclear palsy, corticobasal degeneration, and schizophrenia. The company was formerly known as Amorfix Life Sciences Ltd. and changed its name to ProMIS Neurosciences, Inc. in July 2015. ProMIS Neurosciences, Inc. is headquartered in Toronto, Canada.
Ownership
Ownership Overview
Top Holders
People Also Watch
FAQ
What Is the ProMIS Neurosciences (NASDAQ: PMN) Share Price Today?
The ProMIS Neurosciences stock price today is 13.640 USD.
What Stock Exchange Does ProMIS Neurosciences (PMN) Trade On?
ProMIS Neurosciences is listed and trades on the Nasdaq Stock Exchange.
What Is the Ticker (Stock Symbol) for ProMIS Neurosciences?
The stock symbol (also called a 'ticker') for ProMIS Neurosciences is "PMN."
What Is the Current ProMIS Neurosciences Market Capitalisation?
As of today, ProMIS Neurosciences (NASDAQ: PMN) market cap is 128.820M USD.
What Is ProMIS Neurosciences's (PMN) Earnings Per Share (TTM)?
The ProMIS Neurosciences EPS is currently -8.451 (Trailing Twelve Months).
When Is the Next ProMIS Neurosciences Earnings Date?
ProMIS Neurosciences's next earnings report will be released on 12/05/2026.
Is PMN a Buy or Sell From a Technical Analyst Perspective?
Based on today's ProMIS Neurosciences moving averages and other technical indicators, the daily buy/sell signal for PMN stock is Sell.
How Many Times Has ProMIS Neurosciences Stock Split?
ProMIS Neurosciences has split 2 times. (See the PMN stock split history page for full effective split date and price information.)
How Many Employees Does ProMIS Neurosciences Have?
ProMIS Neurosciences has 11 employees, based on their latest Companies House report.
What is the current trading status of ProMIS Neurosciences (NASDAQ: PMN)?
As of 10/09/2026, ProMIS Neurosciences (PMN) is trading at a share price of 13.640 USD, with a previous close of 14.365 USD. The stock has fluctuated within a day range of 13.240 USD to 13.675 USD, while its 52-week range spans from 6.270 USD to 27.400 USD.
What Is ProMIS Neurosciences (PMN) Price Target According to Analysts?
The average 12-month price target for ProMIS Neurosciences is 43.903 USD, with a high estimate of 100.98297718 USD and a low estimate of 18.32669323 USD. 8 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +221.87% Upside potential.
What Is the PMN Premarket Price?
PMN's last pre-market stock price is 14.000 USD. The pre-market share volume is 33.000, and the stock has decreased by -0.365, or -2.540%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.